Eva-maria M. Fronk

Munich, BY 81379, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Edoxaban for Stroke Prevention in Atrial Fibrillation in Spain and Portugal: 4-Year Follow-Up of the Observational ETNA-AF-Europe Study.

Edoxaban for Stroke Prevention in Atrial Fibrillation in Spain and Portugal: 4-Year Follow-Up of the Observational ETNA-AF-Europe Study.

Journal: Journal of clinical medicine

Published: March 10, 2026

Edoxaban for atrial fibrillation in patients with atherosclerotic disease in daily clinical practice.

Edoxaban for atrial fibrillation in patients with atherosclerotic disease in daily clinical practice.

Journal: Journal of thrombosis and thrombolysis

Published: November 26, 2025

Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making: ENGAGE AF-TIMI 48 Trial Analysis.

Bayesian Machine Learning Model Guiding Iterative, Personalized Anticoagulant Dosing Decision-Making: ENGAGE AF-TIMI 48 Trial Analysis.

Journal: JACC. Advances

Published: October 30, 2025

Comparative Performance of Machine Learning and Traditional Risk Scores in Predicting Adverse Events After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation.

Comparative Performance of Machine Learning and Traditional Risk Scores in Predicting Adverse Events After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation.

Journal: The American journal of cardiology

Published: June 27, 2025

Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe.

Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe.

Journal: Thrombosis and haemostasis

Published: January 17, 2025

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study.

Long-term effectiveness and safety of edoxaban in patients with atrial fibrillation: 4-year data from the ETNA-AF-Europe study.

Journal: International journal of cardiology

Published: January 30, 2024

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry.

Economic burden and health-related quality of life in tenosynovial giant-cell tumour patients in Europe: an observational disease registry.

Journal: Orphanet journal of rare diseases

Published: January 26, 2021

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.

The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.

Journal: Orphanet journal of rare diseases

Published: September 04, 2020

ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.

ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries.

Journal: European journal of internal medicine

Published: June 29, 2020

ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.

ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months.

Journal: Thrombosis research

Published: May 25, 2020

Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE.

Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE.

Journal: European journal of internal medicine

Published: May 02, 2020

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

Correction to: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study.

Journal: Thrombosis journal

Published: June 02, 2018

Showing 1-12 of 20

Last Updated: 09/26/2026